Conference Presentation, Fireside Chat
A Conversation with Francis Collins, Director, National Institutes of Health
- Organizations with greater board and leadership diversity are projected to consistently deliver superior financial results, with plans to request gender data transparency from Fortune 500 companies to enable curative solution development.
- Horizon aims to advance diversity efforts beyond the current pace by utilizing its Inclusion Leadership Council and the CEO Action Pledge, anticipating that distinct team capabilities will yield nimble R&D and faster cures, though a long path remains to achieve representative healthcare leadership.
- The NIH "All of Us" program is supported by Congress for the next 10 years with a goal to enroll one million or more U.S. participants, including children, within two to three years, targeting 50% representation from racial and ethnic minority groups.
- Future clinical trial enrollment is expected to accelerate significantly due to pre-consent within the "All of Us" cohort, with participation rates projected at 50% and a strategy to maintain high retention while building trust with historically excluded communities.
- Genomic data integration is anticipated to become a practical medical tool within the next few years, enabling pharmacogenomics to optimize drug prescribing, though challenges exist in standardizing care delivery nationwide and addressing concerns regarding disability or life insurance discrimination.
- The Brain Initiative, currently 3.5 years into a 10-year timeline, is expected to shift toward applications in the second half with more ambitious goals, potentially aiding treatments for Alzheimer's, Parkinson's, schizophrenia, autism, and addiction.
- Biomedical research funding trends and global competition, particularly from China, influence US leadership prospects, with specific expectations for cures in metastatic cancer, sickle cell disease, HIV/AIDS, and influenza via new vaccines within the next five years.